[1][2] Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 [3] and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE).

[11] The company also received European market approval (CE marking) for NBTXR3 (Hensify®) for the treatment of locally advanced soft tissue sarcoma.

NBTXR3 is an aqueous suspension of crystalline metallic nanoparticles approximately 50 nanometers in diameter, designed for injection directly into a malignant tumor.

[20] Nanobiotix obtained the first European marketing authorization (CE marking) for Hensify, the commercial name of NBTXR3, for the treatment of locally advanced Soft Tissue Sarcoma.

NBTXR3 completed Phase II/III clinical trials to treat Soft tissue sarcomas in combination with radiotherapy and surgery in April 2020.

[8] Chemotherapy in combination with radiation is the standard treatment for locally advanced head and neck cancers in both the United States of America and the European Union.

[citation needed] NBTXR3 is currently in Phase II/III clinical trials to increase radiotherapy’s efficacy at treating Head and neck cancer.

Radiotherapy has been shown to improve outcomes for these patients, as a direct correlation between higher doses of radiation and increased survival rates have been observed from third party clinical trials.

It aims to evaluate the hypothesis that the combination of NBTXR3 activated by RT with anti-PD-1 therapy will act synergistically to enhance the therapeutic window of radiation therapy by maximizing the local effect, overcoming radio-resistance, increasing the efficacy of immunotherapy, and potentially producing an abscopal effect for improved distant tumor control.